York Capital Management Global Advisors LLC decreased its stake in China Biologic Products, Inc. (NASDAQ:CBPO) by 16.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 80,229 shares of the biopharmaceutical company’s stock after selling 16,315 shares during the quarter. York Capital Management Global Advisors LLC owned 0.29% of China Biologic Products worth $9,074,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in shares of China Biologic Products by 694.1% during the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after purchasing an additional 1,318,183 shares during the period. Hillhouse Capital Management Ltd. raised its position in shares of China Biologic Products by 186.8% during the second quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock worth $85,235,000 after purchasing an additional 490,874 shares during the period. Schroder Investment Management Group raised its position in shares of China Biologic Products by 771.5% during the second quarter. Schroder Investment Management Group now owns 544,676 shares of the biopharmaceutical company’s stock worth $60,845,000 after purchasing an additional 482,175 shares during the period. FMR LLC raised its position in shares of China Biologic Products by 27.5% during the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock worth $188,300,000 after purchasing an additional 406,105 shares during the period. Finally, Macquarie Group Ltd. raised its position in shares of China Biologic Products by 115.3% during the second quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock worth $66,456,000 after purchasing an additional 314,700 shares during the period. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/york-capital-management-global-advisors-llc-has-9-07-million-holdings-in-china-biologic-products-inc-cbpo/1613127.html.

A number of equities research analysts have recently commented on CBPO shares. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Jefferies Group LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of China Biologic Products in a research report on Monday, June 12th. Finally, BidaskClub lowered China Biologic Products from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $137.50.

China Biologic Products, Inc. (NASDAQ CBPO) traded up 0.04% during midday trading on Friday, hitting $96.09. The stock had a trading volume of 30,666 shares. The company’s 50 day moving average price is $92.94 and its 200-day moving average price is $103.40. China Biologic Products, Inc. has a 52 week low of $88.25 and a 52 week high of $125.99. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of 25.01 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The business had revenue of $89.28 million for the quarter, compared to the consensus estimate of $97.33 million. During the same period in the prior year, the business earned $1.26 EPS. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities analysts anticipate that China Biologic Products, Inc. will post $4.95 earnings per share for the current fiscal year.

China Biologic Products Company Profile

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.